全文获取类型
收费全文 | 1547篇 |
免费 | 146篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 74篇 |
妇产科学 | 31篇 |
基础医学 | 135篇 |
口腔科学 | 80篇 |
临床医学 | 181篇 |
内科学 | 370篇 |
皮肤病学 | 22篇 |
神经病学 | 34篇 |
特种医学 | 258篇 |
外科学 | 222篇 |
综合类 | 33篇 |
预防医学 | 92篇 |
眼科学 | 14篇 |
药学 | 88篇 |
中国医学 | 2篇 |
肿瘤学 | 82篇 |
出版年
2021年 | 13篇 |
2019年 | 13篇 |
2018年 | 27篇 |
2017年 | 15篇 |
2016年 | 19篇 |
2015年 | 21篇 |
2014年 | 25篇 |
2013年 | 34篇 |
2012年 | 40篇 |
2011年 | 52篇 |
2010年 | 42篇 |
2009年 | 33篇 |
2008年 | 36篇 |
2007年 | 57篇 |
2006年 | 53篇 |
2005年 | 41篇 |
2004年 | 39篇 |
2003年 | 45篇 |
2002年 | 30篇 |
2001年 | 36篇 |
2000年 | 44篇 |
1999年 | 31篇 |
1998年 | 73篇 |
1997年 | 83篇 |
1996年 | 83篇 |
1995年 | 57篇 |
1994年 | 51篇 |
1993年 | 54篇 |
1992年 | 41篇 |
1991年 | 25篇 |
1990年 | 34篇 |
1989年 | 60篇 |
1988年 | 51篇 |
1987年 | 46篇 |
1986年 | 38篇 |
1985年 | 45篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1982年 | 16篇 |
1981年 | 14篇 |
1980年 | 16篇 |
1979年 | 7篇 |
1977年 | 17篇 |
1976年 | 12篇 |
1975年 | 10篇 |
1973年 | 7篇 |
1972年 | 14篇 |
1971年 | 12篇 |
1970年 | 9篇 |
1968年 | 6篇 |
排序方式: 共有1722条查询结果,搜索用时 250 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
3.
Sonoelasticity imaging of prostate cancer: in vitro results 总被引:2,自引:0,他引:2
4.
5.
C. J. Pemberton 《ANZ journal of surgery》2007,77(Z1):A44-A44
Obesity related cardiovascular disease has assumed epidemic proportions and it is important that we properly understand how hormones of metabolism influence cardiac function. Over the last 15 years a multitude of factors have been discovered that appear to play significant roles in energy balance and metabolism, markedly changing our view of fat and GI cells and their dynamic control and regulation of metabolism. This presentation will focus on how three recently discovered hormones Ghrelin, Leptin and Resistin may directly influence cardiac function. Ghrelin is predominately produced and secreted from the X/A cells of the stomach and studies suggest it can act as a cardioprotective agent. However, Ghrelin also acts to constrict the coronary arteries, which places potential limitations upon its therapeutic use. Leptin is produced by adipose tissue in proportion to fat deposition and appears to drive satiety signals in the body. In contrast, Leptin appears to antagonise cardiac function and it may drive the development of hypertension by impairing renal pressure natriuresis and down regulating endothelium derived vasorelaxant factors. The third factor, Resistin, was originally described from rat adipose tissue and was shown to impair insulin action and glucose control. In humans however, Resistin is primarily produced in inflammatory cells such as monocytes and macrophages. Resistin worsens the recovery of the heart from a period of experimental ischemia and promotes the release of inflammatory agents such as tumour necrosis factor‐alpha. Such actions may be partially responsible for the observed insulin resistance after cardiac surgery. 相似文献
6.
7.
8.
9.
10.
Ten thrombocytopenic patients (platelets < 10–24 × 10(9)/L) who were refractory to platelet transfusion were investigated for their responsiveness to staphylococcal protein A column therapy. Nine patients had previously been treated with steroids, intravenous immune globulin, and/or other forms of immunosuppressive therapy without improvement in their transfusion response. All patients were receiving multiple platelet transfusions without achieving 1-hour corrected count increments (CCIs) > or = 7500. Eight patients had antibodies that reacted with platelets and were directed against HLA class I antigens, ABO antigens, and/or platelet-specific alloantigens. Plasma (500-2000 mL) from each patient was passed over a protein A silica gel column and then returned to the patient. Patients received from 1 to 14 treatments. A positive response to protein A therapy was defined as at least a doubling of the pretreatment platelet count and/or two successive 10- to 120-minute posttransfusion CCIs > or = 7500. Following plasma treatments, 6 of 10 patients responded with daily platelet counts that averaged 48 +/− 11 × 10(9) per L as compared with counts of 16 +/− 7 × 10(9) per L (p < 0.0005) before treatment. Posttransfusion CCI values determined in four of these patients averaged 2480 +/− 810 and 10,010 +/− 3540 (p < 0.005) before and after treatment, respectively. In contrast, among the four unresponsive patients, platelet counts averaged 10 +/− 9 and 13 +/− 10 × 10(9) per L (p = NS), respectively, while posttransfusion CCIs were 700 +/− 1410 and 1520 +/− 2460 (p = NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献